Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and ...
The Company expects its existing liquidity, including the revenue it expects to generate from XPOVIO net product sales ... and an anti-CD38 monoclonal antibody (Xd). For the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback